Nissay Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.9M | Buy |
71,463
+1,836
| +3% | +$856K | 0.17% | 96 |
|
|
2025
Q4 | $31.6M | Buy |
69,627
+2,970
| +4% | +$1.28M | 0.16% | 98 |
|
|
2025
Q3 | $26.1M | Buy |
66,657
+1,019
| +2% | +$426K | 0.14% | 108 |
|
|
2025
Q2 | $29.2M | Buy |
65,638
+1,828
| +3% | +$842K | 0.17% | 100 |
|
|
2025
Q1 | $30.9M | Buy |
63,810
+5,568
| +10% | +$2.59M | 0.2% | 86 |
|
|
2024
Q4 | $23.8M | Buy |
58,242
+2,879
| +5% | +$1.33M | 0.15% | 100 |
|
|
2024
Q3 | $25.7M | Buy |
55,363
+3,996
| +8% | +$1.92M | 0.16% | 90 |
|
|
2024
Q2 | $24.1M | Buy |
51,367
+5,242
| +11% | +$2.28M | 0.16% | 85 |
|
|
2024
Q1 | $19.3M | Buy |
46,125
+10,167
| +28% | +$4.3M | 0.13% | 106 |
|
|
2023
Q4 | $14.6M | Buy |
35,958
+3,260
| +10% | +$1.2M | 0.12% | 113 |
|
|
2023
Q3 | $11.4M | Buy |
32,698
+2,190
| +7% | +$766K | 0.1% | 131 |
|
|
2023
Q2 | $10.7M | Sell |
30,508
-218
| -0.7% | -$73.5K | 0.09% | 135 |
|
|
2023
Q1 | $9.68M | Sell |
30,726
-884
| -3% | -$265K | 0.09% | 141 |
|
|
2022
Q4 | $9.13M | Sell |
31,610
-1,204
| -4% | -$367K | 0.09% | 149 |
|
|
2022
Q3 | $9.5M | Buy |
32,814
+1,036
| +3% | +$298K | 0.1% | 126 |
|
|
2022
Q2 | $8.96M | Buy |
31,778
+3,085
| +11% | +$826K | 0.09% | 131 |
|
|
2022
Q1 | $7.49M | Buy |
28,693
+106
| +0.4% | +$25.2K | 0.07% | 179 |
|
|
2021
Q4 | $6.28M | Buy |
28,587
+1,026
| +4% | +$200K | 0.05% | 220 |
|
|
2021
Q3 | $5M | Buy |
27,561
+1,102
| +4% | +$215K | 0.04% | 247 |
|
|
2021
Q2 | $5.33M | Buy |
26,459
+1,508
| +6% | +$315K | 0.05% | 227 |
|
|
2021
Q1 | $5.36M | Sell |
24,951
-624
| -2% | -$137K | 0.05% | 207 |
|
|
2020
Q4 | $6.04M | Sell |
25,575
-1,184
| -4% | -$272K | 0.09% | 183 |
|
|
2020
Q3 | $7.28M | Sell |
26,759
-4,776
| -15% | -$1.32M | 0.12% | 136 |
|
|
2020
Q2 | $9.15M | Buy |
31,535
+1,794
| +6% | +$486K | 0.18% | 121 |
|
|
2020
Q1 | $7.08M | Buy |
29,741
+805
| +3% | +$185K | 0.18% | 127 |
|
|
2019
Q4 | $6.34M | Sell |
28,936
-1,199
| -4% | -$243K | 0.14% | 167 |
|
|
2019
Q3 | $5.11M | Buy |
30,135
+1,919
| +7% | +$339K | 0.12% | 189 |
|
|
2019
Q2 | $5.17M | Sell |
28,216
-1,016
| -3% | -$178K | 0.13% | 176 |
|
|
2019
Q1 | $5.38M | Sell |
29,232
-1,112
| -4% | -$205K | 0.14% | 168 |
|
|
2018
Q4 | $5.03M | Buy |
30,344
+798
| +3% | +$138K | 0.15% | 162 |
|
|
2018
Q3 | $5.7M | Buy |
29,546
+690
| +2% | +$123K | 0.15% | 164 |
|
|
2018
Q2 | $4.9M | Sell |
28,856
-1,277
| -4% | -$198K | 0.14% | 178 |
|
|
2018
Q1 | $4.91M | Sell |
30,133
-1,206
| -4% | -$197K | 0.15% | 173 |
|
|
2017
Q4 | $4.7M | Buy |
+31,339
| New | +$4.64M | 0.14% | 187 |
|
Other funds holding VRTX
VCM
VPM
Nissay Asset Management's VRTX Position: Q1 2026 in Review
Nissay Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q1 2026, buying an estimated $856K and bringing the position to 71,463 shares worth $31.9M. The position accounts for 0.17% of the portfolio, ranked #96.
Nissay Asset Management first reported a position in VRTX in Q4 2017 and has held it in 34 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Nissay Asset Management held 71,463 shares of Vertex Pharmaceuticals worth $31.9M as of Q1 2026.
- Nissay Asset Management bought 1,836 Vertex Pharmaceuticals shares in Q1 2026, an estimated $856K.
- Vertex Pharmaceuticals made up 0.17% of Nissay Asset Management's portfolio in Q1 2026, its #96 holding.
- Nissay Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Nissay Asset Management's 13F filing for Q1 2026, filed 15 May 2026.